BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21890643)

  • 1. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
    McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
    Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
    Dale DC; Bolyard AA; Kelley ML; Westrup EC; Makaryan V; Aprikyan A; Wood B; Hsu FJ
    Blood; 2011 Nov; 118(18):4963-6. PubMed ID: 21835955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
    McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
    Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
    Dotta L; Tassone L; Badolato R
    Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
    McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
    J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
    McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
    J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor for the Treatment of WHIM Syndrome.
    McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM
    N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics on a WHIM.
    Al Ustwani O; Kurzrock R; Wetzler M
    Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
    Badolato R; Dotta L; Tassone L; Amendola G; Porta F; Locatelli F; Notarangelo LD; Bertrand Y; Bachelerie F; Donadieu J
    J Pediatr; 2012 Oct; 161(4):763-5. PubMed ID: 22748845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
    Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
    Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A WHIM satisfactorily addressed.
    Broxmeyer HE
    Blood; 2014 Apr; 123(15):2286-8. PubMed ID: 24723677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs.
    Majumdar S; Pontejo SM; Jaiswal H; Gao JL; Salancy A; Stassenko E; Yamane H; McDermott DH; Balabanian K; Bachelerie F; Murphy PM
    J Immunol; 2023 Jun; 210(12):1913-1924. PubMed ID: 37133343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
    Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
    Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
    De Clercq E
    Antivir Chem Chemother; 2019; 27():2040206619829382. PubMed ID: 30776910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Hematologic Effects of Endotoxin in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome Model Mice.
    Majumdar S; Gao JL; Pontejo SM; Balabanian K; Bachelerie F; Murphy PM
    Immunohorizons; 2022 Jul; 6(7):543-558. PubMed ID: 35882421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
    Merati N; Sivachandran S; Jfri A; Ben-Shoshan M; Vinh DC; Popradi G; Litvinov IV
    Skin Therapy Lett; 2022 Mar; 27(2):1-5. PubMed ID: 35385630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.
    Liu Q; Chen H; Ojode T; Gao X; Anaya-O'Brien S; Turner NA; Ulrick J; DeCastro R; Kelly C; Cardones AR; Gold SH; Hwang EI; Wechsler DS; Malech HL; Murphy PM; McDermott DH
    Blood; 2012 Jul; 120(1):181-9. PubMed ID: 22596258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.
    de Wit RH; Heukers R; Brink HJ; Arsova A; Maussang D; Cutolo P; Strubbe B; Vischer HF; Bachelerie F; Smit MJ
    J Pharmacol Exp Ther; 2017 Oct; 363(1):35-44. PubMed ID: 28768817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.
    Dotta L; Notarangelo LD; Moratto D; Kumar R; Porta F; Soresina A; Lougaris V; Plebani A; Smith CIE; Norlin AC; Gòmez Raccio AC; Bubanska E; Bertolini P; Amendola G; Visentini M; Fiorilli M; Venuti A; Badolato R
    J Allergy Clin Immunol Pract; 2019; 7(5):1568-1577. PubMed ID: 30716504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome.
    Bachelerie F
    Dis Markers; 2010; 29(3-4):189-98. PubMed ID: 21178277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.